Planned
Innovation at Speratum
Innovation drives everything at Speratum Biopharma
Our Proprietary Platforms
At Speratum Biopharma, we are unlocking the power of RNA interference (RNAi) to transform how diseases—especially cancer—are understood, targeted, and treated. RNAi is a naturally occurring cellular mechanism that regulates gene expression by silencing specific messenger RNA (mRNA) molecules, effectively preventing the production of disease-driving proteins. By harnessing this mechanism, we can directly interfere with the biological pathways responsible for tumor growth, resistance, and progression.
Our approach is built around the belief that precision gene silencing—delivered with safety and scalability—can change the treatment paradigm for patients with difficult-to-treat cancers. While other companies rely on lipid nanoparticles, viral vectors, or conjugate-based delivery, Speratum Biopharma has developed a first-of-its-kind dual-polymeric nanoparticle delivery system designed specifically for RNAi-based therapeutics.
Our proprietary platforms include:
NoPass™ – a breakthrough formulation of engineered RNAi payloads that precisely target and silence disease-driving genes at the mRNA level, disrupting the underlying biology of cancer.
Nano-In™ – our electrostatically tuned polymeric delivery platform that enables efficient, targeted delivery of RNAi molecules directly to tumor tissue. Nano-In™ offers biocompatibility, high stability, flexible administration routes (IV, intratumoral, intraperitoneal), and avoids common pitfalls such as cold chain dependency, hepatotoxicity, or immune activation.
This modular system allows us to tailor RNAi therapeutics to different disease models and tissue types, making it adaptable, scalable, and uniquely positioned for both clinical and commercial success.
At Speratum, our scientific team has spent years perfecting the balance between biological effectiveness and delivery precision—engineering next-generation RNAi therapies that go beyond temporary symptom relief to target disease at its source. Our RNAi therapeutics are built to silence—not just slow—oncogenic pathways.
This is RNAi reimagined: clinically actionable, delivery-optimized, and built for the patients who need it most.
NoPass Design
The NoPass™ platform represents a next-generation innovation in RNA interference (RNAi) therapy design. It is built as a proprietary RNAi-based scaffold engineered to regulate complex, dysregulated signaling networks that drive cancer progression. Acting as a central control node, NoPass is designed to simultaneously suppress tumor growth, limit metastasis, and overcome resistance to therapy by targeting multiple oncogenic pathways in a coordinated, intelligent manner. What sets NoPass apart is its precision algorithmic design—a suite of proprietary tools that generate RNAi molecules with enhanced specificity, minimized off-target activity, and increased potency. These intelligently engineered molecules overcome the traditional limitations of RNA therapeutics, offering a more predictable, modular, and potent therapeutic output. NoPass orchestrates precision through intelligent RNAi engineering—delivering a level of therapeutic breadth typically associated with microRNA and the precision and targetability of siRNA, without being confined to either class.
Nano-In
The Nano-In™ Platform is a revolutionary drug delivery system. Utilizing a proprietary biocompatible polymer, Nano-In™ forms nanoparticles that precisely target cancer cells. This platform optimizes the delivery of nucleic acids directly to tumor sites, ensuring protection from degradation, maximizing potency, and minimizing off-target effects. The result is a delivery system that reduces toxicity while enhancing therapeutic impact, leading to safer and more effective treatments.
NM-198 Fully loaded
NM-198 is Speratum’s flagship RNAi candidate. Built on the combined strengths of NoPass™ and Nano-In™, this therapeutic platform targets multiple drivers of tumor biology—growth, invasion, and resistance—while ensuring safe and efficient delivery. The result is a novel RNAi-based treatment with the potential to redefine outcomes in precision oncology.
Focus Areas
Our goal is to deliver safer, more effective, and tailored treatments, particularly for cancers with limited options. We hold patents across multiple cancer types, including pancreatic, colon, ovarian, gastric, and lung, among others, for our miR-198-based therapy, which has shown potent tumor-suppressive effects across solid tumors, underscoring its broad applicability in oncology.
Lungs
Kidney
Pancreatic
Colon
Gastric
Ovarian
Breast
Cervical
Osteosarcoma
Other Cancer
Product Development Portfolio
We leverage robust platforms and a data-driven approach to drive proactive drug development. Our product development portfolio spans from preclinical research to First-in-Human trials, advancing innovation in oncology. Additionally, we offer platform development opportunities for co-development or licensing, expanding the impact of our technologies and enabling strategic collaborations.
Program
Indication
Discovery
Preclinical
Phase I
Phase II
Phase III
NM-198
NM-520
NM-V1
Why Partner with Speratum Biopharma?
At Speratum Biopharma, we are redefining the future of cancer therapy through the power of RNA interference (RNAi). Our mission is bold yet focused: to silence the root causes of disease by precisely targeting the genetic messengers that drive tumor growth, resistance, and metastasis.
While currently in the preclinical stage, our programs are built on a foundation of rigorous science, innovative delivery platforms, and a clear path to clinical translation. We are actively advancing toward first-in-human trials, with a projected launch in late 2025 or early 2026. Every element of our platform—from payload to delivery—is designed with scalability, safety, and therapeutic durability in mind.
The name Speratum is derived from Latin, meaning “hope.” For us, it stands for more than a name—it’s a mindset. We define HOPE as: Harnessing Opportunities to Pioneer Excellence in RNAi therapeutics.
By partnering with Speratum Biopharma, you’re joining a team that merges deep scientific insight with operational readiness and an unwavering commitment to innovation. Together, we can accelerate the development of first-in-class therapies and bring transformative solutions to patients facing the most challenging cancers.
Let’s silence cancer—at the source.